Effects of 22-oxa-calcitriol on podocyte injury in adriamycin-induced nephrosis

American Journal of Nephrology

Volumn 35, Issue 1, 2012, Pages 58-68

  Lydia, Aida ^a,b   Asanuma, Katsuhiko ^a   Nonaka, Kanae ^a   Takagi, Miyuki ^a   Jeong, Kyung Hwan ^a,c   Kodama, Fumiko ^a   Asao, Rin ^a   Asanuma, Etsuko ^a   Prodjosudjadi, Wiguno ^b   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c Kyung Hee University   (South Korea)

Author keywords

22 oxa calcitriol; Adriamycin induced nephrosis; Glomerulosclerosis; Podocyte injury; Proteinuria

Indexed keywords

22 OXACALCITRIOL; CD2 ASSOCIATED PROTEIN; DOXORUBICIN; NEPHRIN; PODOCIN; VITAMIN D DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL COUNT; CELL DAMAGE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; IMMUNOFLUORESCENCE; KIDNEY FIBROSIS; MOUSE; NEPHROSIS; NICK END LABELING; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CALCITRIOL; DOXORUBICIN; FEMALE; FIBROSIS; IN SITU NICK-END LABELING; KIDNEY DISEASES; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; MICROSCOPY, FLUORESCENCE; NEPHROSIS; PODOCYTES; PROTEINURIA; SCLEROSIS; TIME FACTORS; VITAMIN D;

EID: 83755206827     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000334626     Document Type: Article

References (47)

1. Kritz W, Lemley KV: The role of podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 1999; 8: 489-497.
2. Kerjaschki D: Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001; 108:1583-1587. (Pubitemid 33144868)
3. Shankland SJ: The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147. (Pubitemid 43882099)
4. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945. (Pubitemid 26114159)
5. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G: How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002; 13: 2898-2908. (Pubitemid 35386909)
6. Ohara I, Tanimoto M, Gohda T, Yamazaki T, Hagiwara S, Murakoshi M, Aoki T, Toyoda H, Ishikawa Y, Funabiki K, Horikoshi S, Tomino Y: Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D3 in type 2 diabetic nephropathy in KK-A(y)/Ta mice. Nephron Exp Nephrol 2011; 117:e124-e132.
7. Kuhlmann A, Haas CS, Gross M-L, Reulbach U, Holzinger M, Schwarz U, Ritz E, Amann K: 1,25-Dihydroxyvitamin D 3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286:F526-F533. (Pubitemid 38233647)
8. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, Abe H, Kuze K, Fukatsu A, Kita T, Doi T: A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001; 158: 1733-1741. (Pubitemid 32422938)
9. Panichi V, Migliori M, Taccola D, Filippi C, Nisco LD, Giovannini L, Palla R, Tetta C, Camussi G: Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 2001; 60: 87-95. (Pubitemid 32587543)
10. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E: Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rat. Kidney Int 1998; 53: 1696-1705. (Pubitemid 28243754)
11. Stumpf WE, Sar M, Reid FA, Tanaka Y, Deluca HF: Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979; 206: 1188-1190. (Pubitemid 10159658)
12. Asanuma K, Akiba-Takagi M, Kodama F, Asao R, Nagai Y, Lydia A, Fukuda H, Tanaka E, Shibata T, Takahara H, Hidaka T, Asanuma E, Kominami E, Ueno T, Tomino Y: Dendrin location in podocytes is associated with disease progression in animal and human glomerulopathy. Am J Nephrol 2011; 33: 537-549.
13. Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, Tomino Y: Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 2004; 53: 1473-1479. (Pubitemid 39410389)
14. Schwarz K, Simons M, Reiser J, Saleem MA, Faul C, Kriz W, Shaw AS, Holzman LB, Mundel P: Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001; 108: 1583-1587.
15. Asanuma K, Campbell KN, Kim K, Faul C, Mundel P: Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes. PNAS 2007; 104: 10134-10139. (Pubitemid 47175275)
16. Tang S, Leung J, Chan L, Eddy A, Lai K: Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy. Kidney Int 2008; 73: 288-299.
17. Sugiyama H, Kobayashi M, Wang D-H, Sunami R, Maeshima Y, Yamasaki Y, Masuoka N, Kira S, Makino H: Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral obstruction in acatalasemic mice. Nephrol Dial Transplant 2005; 20: 2670-2680. (Pubitemid 41672265)
18. Macconi D, Bonomelli M, Benigni A, Plati T, Sangalli F, Longaretti L, Conti S, Kawachi H, Hill P, Remuzzi G, Remuzzi A: Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. Am J Pathol 2006; 1: 42-54. (Pubitemid 43062558)
19. Asanuma K, Kim K, Oh J, Giardino L, Chabanis S, Faul C, Reiser J, Mundel P: Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner.. J Clin Invest 2005; 5: 1888-1198.
20. Asanuma K, Tanida I, Shirato I, Ueno T, Takahara H, Nishitani T, Kominami E, Tomino Y: MAP-LC3, a promising autophagosomal marker, is processed during the differentiation and recovery of podocytes from PAN nephrosis. FASEB J 2003; 17: 1165-1187.
21. Gassler N, Elger M, Kranzlin B, Kriz W, Gretz N, Hosser H, Hartmann I: Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat. Kidney Int 2001; 60: 106-116. (Pubitemid 32587545)
22. Kim YH, Goyal M, Kurnit D, et al: Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60: 957-968. (Pubitemid 34205795)
23. Macconi D, Bonomelli M, Benigni A, Plati T, Sangalli F, Langaretti L, Conyi S, Kawachi H, Hill P, Remuzzi G, Remuzzi A: Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. Am J Pathol 2006; 168: 42-54. (Pubitemid 43062558)
24. Mundel P, Shankland SJ: Podocyte biology and response to injury. J Am Soc Nephrol 2002; 13: 3005-3015. (Pubitemid 35386921)
25. Wiggins R: The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007; 71: 1205-1214. (Pubitemid 46884251)
26. Kriz W, Gretz N, Lemley KV: Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697. (Pubitemid 28397387)
27. Asanuma K, Yanagida-Asanuma E, Takagi M, Kodama F, Tomino Y: The role of podocytes in proteinuria. Nephrology 2007; 12:S15-S20. (Pubitemid 350077387)
28. Migliori M, Giovannini L, Panichi V, Filippi C, Taccola D, Origlia N, Mannari C, Camussi G: Treatment with 1,25-dihydroxyvitamin D3 preserves glomerular slit diaphragm-associated protein expression in experimental glomerulonephritis. Int J Immunopathol Pharmacol 2005; 18: 779-790.
29. Furness PN, Hall LL, Shaw JA, Pringle JH: Glomerular expression of nephrin is decreased in acquired human nephrotic syndrome. Nephrol Dial Transplant 1999; 14: 1234-1237. (Pubitemid 29209313)
30. Toyoda M, Suzuki D, Umezono T: Expression of human nephrin mRNA in diabetic neph ropathy. Nephrol Dial Transplant 2004; 19: 380-385. (Pubitemid 38195987)
31. Wang SX, Rastaldi MP, Patari A: Patterns of nephrin and new proteinuria-associated protein expression in human diseases. Kidney Int 2002; 61: 141-147. (Pubitemid 34075140)
32. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, Quigg RJ, Li YC: Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008; 73: 163-171.
33. Yamauchi K, Takano Y, Kasai A, Hayakawa K, Hiramatsu N, Enomoto N, Yao J, Kitamura M: Screening and identification of substances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int 2006; 70: 892-900. (Pubitemid 44285966)
34. Asanuma K, Mundel P: The role of podocytes in glomerular pathobiology. Clin Exp Nephrol 2003; 7: 255-259. (Pubitemid 38031285)
35. Yaddanapudi S, Altintas MM, Kistler A, Fernandez I, Moller CC, Wei C, Peev V, Flesche JB, Forst AL, Li J, Patrakka J, Xiao Z, Grahammer F, Schiffer M, Lohmuller T, Reinheckel T, Gu R, Huber TB, Ju W, Bitzer M, Rastaldi MP, Ruiz P, Tryggvason K, Shaw A, Faul C, Sever S, Reiser J: CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest 2011; 121: 3965-3980.
36. Suarez IG, Redwood AB, Grotsky DA, Neumann MA, Cheng EHY, Stewart CL, Dusso A, Gonzalo S: A new pathway that regulates 53BP1 stability implicates Cathepsin L and vitamin D in DNA repair. EMBO J 2011; 16: 3383-3396.
37. Xiao H, Shi W, Liu S, Wang W, Zhang B, Zhang Y, Xu L, Liang X, Liang Y: 1,25-Dihydroxyvitamin D3 prevents puromycin aminonucleoside- induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am J Nephrol 2009; 30: 34-43.
38. Wagner N, Wagner KD, Schley G, Badiali L, Theres H, Scholz H: 1,25-dihydroxyvitamin D3 -induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl-2 and bax. Exp Eye Res 2003; 77: 1-9. (Pubitemid 36776268)
39. Valrance ME, Welsh J: Breast cancer cell regulation by high-dose vitamin D compounds in the absence of nuclear vitamin D receptor. J Steroid Biochem Mol Biol 2004; 89-90: 221-225. (Pubitemid 38844286)
40. Diker-Cohen T, Koren R, Liberman UA, Ravid A: Vitamin D protects keratinocytes from apoptosis induced by osmotic shock, oxidative stress, and tumor necrosis factor. Ann N Y Acad Sci 2003; 1010: 350-353. (Pubitemid 38265005)
41. Christakos S, Liu Y: Biological actions and mechanism of action of calbindin in the process of apoptosis. J Steroid Biochem Mol Biol 2004; 89-90: 401-404. (Pubitemid 38844319)
42. Vertino AM, Bula CM, Chen JR, Almeida M, Han L, Bellido T, Kousteni S, Norman AW, Manolagan S: Nongenotropic, anti-apoptotic signaling of 1 α,25(OH)2 -vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes. J Biol Chem 2005; 280: 14130-14137. (Pubitemid 40517315)
43. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Iturbe BR: Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74: 1394-1402.
44. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E: Combination therapy with an angiotensinconverting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-1806. (Pubitemid 46870316)
45. Rodriguez-Iturbe B, Romeo F, Johnson RJ: Pathophysiological mechanisms in salt-dependent hypertension. Am J Kidney Dis 2007; 50: 655-672.
46. Furuichi T, Kawata S, Asoh Y, Kumaki K, Ohyama Y: Differential time course of induction of 1 alfa,25-dihydroxyvitamin D3-24 hydroxylase mRNA expression in rats by 1 alfa,25-dihydroxyvitamin D3 and its analogs. Life Sci 1998; 62: 453-459. (Pubitemid 28018199)
47. Brown AJ, Finchi J, Grieff M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E: The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993; 133: 1158-1164. (Pubitemid 23267767)